Qiagen (NYSE:QGEN) Shares Bought by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. grew its position in Qiagen (NYSE:QGEN) by 34.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,409 shares of the company’s stock after buying an additional 4,225 shares during the period. Assenagon Asset Management S.A.’s holdings in Qiagen were worth $731,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in QGEN. Wellington Management Group LLP grew its position in Qiagen by 77.7% in the third quarter. Wellington Management Group LLP now owns 21,250,943 shares of the company’s stock worth $963,386,000 after acquiring an additional 9,293,040 shares during the period. Barclays PLC boosted its stake in Qiagen by 170.6% during the third quarter. Barclays PLC now owns 1,849,004 shares of the company’s stock worth $84,259,000 after buying an additional 1,165,594 shares during the period. Victory Capital Management Inc. lifted its stake in Qiagen by 62.6% during the third quarter. Victory Capital Management Inc. now owns 2,574,705 shares of the company’s stock worth $117,329,000 after purchasing an additional 991,325 shares in the last quarter. Point72 DIFC Ltd lifted its stake in Qiagen by 10,610.4% during the third quarter. Point72 DIFC Ltd now owns 649,693 shares of the company’s stock worth $29,606,000 after purchasing an additional 643,627 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Qiagen by 36.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,604,034 shares of the company’s stock valued at $73,096,000 after buying an additional 424,937 shares during the period. Institutional investors and hedge funds own 70.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Jefferies Financial Group reaffirmed a “buy” rating and issued a $54.00 target price (up from $42.00) on shares of Qiagen in a research report on Tuesday, December 10th. Morgan Stanley reaffirmed an “equal weight” rating and set a $48.00 target price (down from $50.00) on shares of Qiagen in a research note on Monday, January 6th. Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research report on Thursday, October 17th. Finally, HSBC lowered Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective on the stock. in a research report on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $51.50.

Qiagen Price Performance

Shares of QGEN opened at $45.70 on Friday. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39. The firm’s fifty day simple moving average is $44.60 and its 200-day simple moving average is $44.27. The firm has a market capitalization of $10.43 billion, a price-to-earnings ratio of 117.18, a PEG ratio of 3.49 and a beta of 0.37. Qiagen has a twelve month low of $39.03 and a twelve month high of $47.93.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.